Controlled and uncontrolled asthma display distinct alveolar tissue matrix compositions

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Weitoft, Maria ^a   Andersson, Cecilia ^b   Andersson Sjöland, Annika ^a   Tufvesson, Ellen ^b   Bjermer, Leif ^b   Erjefält, Jonas ^a   Westergren Thorsson, Gunilla ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Alveolar parenchyma; Asthma; Controlled; Extracellular matrix; ICS; Myofibroblasts; Remodeling; Uncontrolled

Indexed keywords

ALTERNATIVELY SPLICED DOMAIN A OF FIBRONECTIN; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIGLYCAN; BRONCHODILATING AGENT; COLLAGEN; DECORIN; FIBRONECTIN; GELATINASE B; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; STEROID; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; VERSICAN; CORTICOSTEROID; MMP9 PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN;

ADULT; AIRWAY DYNAMICS; ALLERGIC ASTHMA; ARTICLE; BRONCHUS BIOPSY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED ATOPIC ASTHMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE CONTROL; EXTRACELLULAR MATRIX; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS; LUNG FIBROBLAST; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MYOFIBROBLAST; PROTEIN EXPRESSION; SPIROMETRY; STEROID THERAPY; TISSUE STRUCTURE; TRANSBRONCHIAL BIOPSY; UNCONTROLLED ATOPIC ASTHMA; ASTHMA; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ASTHMA; CELLS, CULTURED; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY ALVEOLI; TISSUE INHIBITOR OF METALLOPROTEINASE-3; YOUNG ADULT;

EID: 84902707564     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-67     Document Type: Article

References (45)

1. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8:183-192.
2. Busse WW, Lemanske RF. Asthma. N Engl J Med 2001, 344:350-362.
3. Holgate ST. Novel targets of therapy in asthma. Curr Opin Pulm Med 2009, 15:63-71.
4. Global initiative for asthma. GINA report, global strategy for asthma management and prevention. http://www.ginasthma.org.
5. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, Accordini S, Almar E, Bugiani M, Carolei A, Cerveri I, Duran-Tauleria E, Gislason D, Gulsvik A, Jogi R, Marinoni A, Martinez-Moratalla J, Vermeire P, Marco R. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007, 120:1360-1367.
6. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002, 109:S447-S460.
7. Bergeron C, Hauber HP, Gotfried M, Newman K, Dhanda R, Servi RJ, Ludwig MS, Hamid Q. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005, 116:983-989.
8. Andersson CK, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefalt JS. Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol 2011, 127:905-912. e901-907.
9. Kraft M, Martin RJ, Wilson S, Djukanovic R, Holgate ST. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999, 159:228-234.
10. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002, 20:254-259.
11. Huang J, Olivenstein R, Taha R, Hamid Q, Ludwig M. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. Am J Respir Crit Care Med 1999, 160:725-729.
12. Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin Immunol 2007, 120:997-1009. quiz 1010-1001.
13. de Medeiros MM, da Silva LF, dos Santos MA, Fernezlian S, Schrumpf JA, Roughley P, Hiemstra PS, Saldiva PH, Mauad T, Dolhnikoff M. Airway proteoglycans are differentially altered in fatal asthma. J Pathol 2005, 207:102-110.
14. Muliol J, Maurer M, Bousquet J. Sleep and allergic rhinitis. J Investig Allergol Clin Immunol 2008, 18:415-419.
15. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM, Grone HP. The matrix component biglycan is proinflammatory and signals through toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005, 115:2223-2233.
16. Tufvesson E, Westergren-Thorsson G. Biglycan and decorin induce morphological and cytoskeletal changes involving signalling by the small GTPases RhoA and Rac1 resulting in lung fibroblast migration. J Cell Sci 2003, 116:4857-4864.
17. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
18. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
19. Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M, Tabuena R, Chin K, Mio T, Ito Y, Muro S, Hirai T, Morita S, Fukuhara S, Mishima M. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005, 60:277-281.
20. Nihlberg K, Andersson-Sjoland A, Tufvesson E, Erjefalt JS, Bjermer L, Westergren-Thorsson G. Altered matrix production in the distal airways of individuals with asthma. Thorax 2010, 65:670-676.
21. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, Kosinski M, Pendergraft TB, Jhingran P. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006, 117:549-556.
22. Raghu G, Masta S, Meyers D, Narayanan AS. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta. Am Rev Respir Dis 1989, 140:95-100.
23. Howell JE, McAnulty RJ. TGF-beta: its role in asthma and therapeutic potential. Curr Drug Targets 2006, 7:547-565.
24. Bergqvist A, Andersson CK, Hoffmann HJ, Mori M, Shikhagaie M, Krohn IK, Dahl R, Bjermer L, Erjefalt JS. Marked epithelial cell pathology and leukocyte paucity in persistently symptomatic severe asthma. Am J Respir Crit Care Med 2013, 188:1475-1477.
25. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 2010, 29:248-253.
26. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, Ruoslahti E. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994, 302(Pt 2):527-534.
27. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1327-L1334.
28. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGFbeta axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 2012, 60:262-268.
29. Geng Y, McQuillan D, Roughley PJ. SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol 2006, 25:484-491.
30. Kuwaba K, Kobayashi M, Nomura Y, Irie S, Koyama Y. Elongated dermatan sulphate in post-inflammatory healing skin distributes among collagen fibrils separated by enlarged interfibrillar gaps. Biochem J 2001, 358:157-163.
31. Ruhland C, Schonherr E, Robenek H, Hansen U, Iozzo RV, Bruckner P, Seidler DG. The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J 2007, 274:4246-4255.
32. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997, 136:729-743.
33. Evanko SP, Tammi MI, Tammi RH, Wight TN. Hyaluronan-dependent pericellular matrix. Adv Drug Deliv Rev 2007, 59:1351-1365.
34. Isogai Z, Aspberg A, Keene DR, Ono RN, Reinhardt DP, Sakai LY. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem 2002, 277:4565-4572.
35. Wight TN, Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004, 94:1158-1167.
36. Du WW, Yang W, Yee AJ. Roles of versican in cancer biology-tumorigenesis, progression and metastasis. Histol Histopathol 2013, 28:701-713.
37. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002, 14:617-623.
38. Merrilees MJ, Ching PS, Beaumont B, Hinek A, Wight TN, Black PN. Changes in elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonary disease. Respir Res 2008, 9:41.
39. Todorova L, Gurcan E, Miller-Larsson A, Westergren-Thorsson G. Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol. Am J Respir Cell Mol Biol 2006, 34:92-100.
40. Miller M, Cho JY, McElwain K, McElwain S, Shim JY, Manni M, Baek JS, Broide DH. Corticosteroids prevent myofibroblast accumulation and airway remodeling in mice. Am J Physiol Lung Cell Mol Physiol 2006, 290:L162-L169.
41. Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997, 17:326-333.
42. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001, 194:809-821.
43. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998, 101:2129-2139.
44. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000, 292:988-994.
45. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012, 130:829-842. quiz 843-824.